NRC-2694-A + Paclitaxel
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma
Conditions
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Trial Timeline
Sep 30, 2022 → Jun 30, 2027
NCT ID
NCT05283226About NRC-2694-A + Paclitaxel
NRC-2694-A + Paclitaxel is a phase 2 stage product being developed by Natco Pharma for Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05283226. Target conditions include Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05283226 | Phase 2 | Recruiting |
Competing Products
20 competing products in Carcinoma